REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
Thursday, July 25, 2002 BiopharmaWatch Research 1 min read
Key Takeaway: REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
REGENERON COMPLETES ENROLLMENT OF PHASE III STUDIES FOR SHORT-TERM TREATMENT REGIMENS WITH AXOKINE(R) FOR OBESITY STUDIES WILL MEASURE SHORTER DOSING PERIODS AND SUBJECTS' ABILITY TO MAINTAIN WEIGHT LOSS WITHOUT RAPID WEIGHT GAIN FOLLOWING CESSATION OF TREATMENT.